Related Experiment Video
Updated: Jan 12, 2026
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
9.3K
Reduction of C. difficile-associated disease using a multifaceted approach.
Numair Damani1, Ruth Montgomery2, Stephen Wallace2
1The Malthouse Surgery, The Charter, Abingdon, UK.
Journal of Infection Prevention
|November 3, 2025
Summary
Clostridioides difficile infection (CDI) is a major healthcare threat. A multifaceted intervention strategy successfully reduced CDI episodes by 77% in one year, demonstrating its effectiveness in combating this infection.
Area of Science:
- Infectious Diseases
- Healthcare Epidemiology
- Public Health Interventions
Background:
- Clostridioides difficile is a primary cause of hospital-acquired diarrhea, leading to significant morbidity and mortality.
- Symptoms range from mild diarrhea to severe pseudomembranous colitis and death.
- A rise in Clostridioides difficile infection (CDI) cases was observed in 2008.
Purpose of the Study:
- To evaluate the impact of a multifaceted intervention strategy on reducing CDI episodes.
- To assess the long-term effectiveness of the intervention in a healthcare setting.
Main Methods:
- Implementation of a multifaceted approach by the Southern Health and Social Care Trust (SHSCT) to combat CDI.
- Monitoring CDI episodes in hospital patients before and after intervention implementation.
Main Results:
- CDI episodes in patients aged over 65 decreased by 77% within the first year (from 164 in 2008-09 to 37 in 2009-10).
- A sustained reduction in CDI episodes was observed, with a 64% decrease by 2021/2022 compared to 2008/09.
- The intervention led to a significant decrease in hospital-acquired CDI.
Conclusions:
- Multifaceted intervention strategies are crucial for decreasing the incidence of healthcare-acquired CDI.
- Successful implementation of such strategies can lead to substantial reductions in CDI rates.
- Continued monitoring and intervention are necessary to maintain low CDI incidence.
Related Concept Videos
01:22Healthcare Associated Infections II: Preventive Measures
3.6K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.6K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
463
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
463
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
01:26Peptic Ulcer Disease IV: Management
424
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
424
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.1K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
615
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
615